About Us

Dr. Cheryl London, DVM, PhD, ACVIM (Oncology) is a Research Professor at Cummings School of Veterinary Medicine at Tufts University and the Molecular Oncology Research Institute at Tufts Medical Center. She has an active laboratory research program centered on comparative and translational oncology and is involved in the training of graduate students and postdoctoral fellows. She has recently joined the Clinical Trials Office at Cummings School to expand operations and enhance capacity and breadth of trials performed in client-owned animals.

Dr. London is also an Associate Faculty Professor at the Ohio State University College of Veterinary Medicine (OSU CVM) where she remains Director of the Clinical Trials Office at the CVM and Director of Translational Therapeutics at the Center for Clinical and Translational Sciences, OSU College of Medicine. Prior to her time at OSU, she was an Assistant Professor in the Department of Surgical and Radiological Sciences at the University of California, Davis.

Dr. London earned her Doctor of Veterinary Medicine at Cummings School, completed her residency in medical oncology at the University of Wisconsin-Madison and received her PhD in immunology at Harvard University, where she was also a postdoctoral fellow in the Department of Pathology.

Dr. London’s expanded bio
Follow Tufts Vet on Twitter

How dogs are teaching researchers new tricks for treating cancer by Sarah DeWeerdt, Nature

How Are Dogs Helping Us Cure Cancer in People? by Elaine K. Howley, U.S. News

Dr. Mason’s lab focuses on developing novel approaches to generate functional, tumor-specific cytotoxic T lymphocytes. One approach involves active immunization using whole tumor RNA loaded CD40 activated B cells, aimed at activating tumor specific T cells in vivo. A second approach involves the passive adoptive transfer of genetically modified autologous T cells that are capable of MHC-independent tumor antigen recognition and activation/effector function in the absence of co-stimulatory ligands.

A second related focus of Dr. Mason’s lab is to identify novel tumor-associated antigens and to develop single-chain Fragment variable targeting systems that can be used alone or in concert with cell based therapies to target spontaneous occurring tumors. Through innovative clinical trials in canine cancer patients, the lab is working in concert with clinical oncologists to evaluate the safety and efficacy of both active immunization and passive adoptive transfer of genetically modified T cells in the treatment of spontaneously occurring cancer.

Dr. Mason’s expanded bio
Follow Penn Vet on Twitter

New tricks in canine cancer research may improve treatments for humans, too By Laurie McGinley, The Washington Post

Dr. Ravi Tolwani oversees the Gene Targeting Resource Center and Transgenic Services Laboratory of the Comparative Bioscience Center (CBC). The CBC provides expertise in animal models, research design and methodology, generation and evaluation of genetically engineered mouse models, and other collaborative efforts. It also provides training to Rockefeller investigators.

Dr. Tolwani holds a Doctor of Veterinary Medicine from Auburn University. After two years in private practice in Nashville, Tennessee, he turned to research, completing a Ph.D. in cellular and molecular pathology, and a postdoc fellowship in laboratory animal/comparative medicine at the University of Alabama. For his research, he developed a mouse model to study a common illness in humans associated with an enzyme deficiency in fat metabolism. Tolwani later earned an M.Sx. degree in management from the Stanford Graduate School of Business.

Dr. Ravi Tolwani Tolwani joined Rockefeller in 2007. From 1994 to 2007, he served on the faculty of the Stanford University School of Medicine, where his laboratory focused on understanding the molecular mechanisms of brain plasticity.

Dr. Tolwani’s expanded bio
Follow Dr. Tolwani on Twitter

Corrie Painter is the Deputy Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focused on melanoma. In 2010, Painter was diagnosed with breast angiosarcoma. She has combined her cancer advocacy and scientific background to engage with patients in order to build and carry out patient-partnered genomics studies such as the Metastatic Breast Cancer Project (MBCproject.org). She is also the co-founder of Angiosarcoma Awareness Inc.

Dr. Painter’s expanded bio
Follow Dr. Painter on Twitter

Dr. Karlsson is an Associate Professor, Program in Bioinformatics and Integrative Biology, and Program in Molecular Medicine, UMass Chan Medical School. She is also the director of the Vertebrate Genomics Group at the Broad Institute of MIT and Harvard. Dr. Karlsson is excited by the potential for using our own evolutionary history to understand how the human genome works, and how that knowledge can lead to advances in healthcare.

Karlsson has a special interest in diseases shared between humans and dogs. She leads the citizen science-driven Darwin’s Dogs project, which invites all dog owners to participate directly in research exploring the genetic basis of dog behavior, as well as diseases such as OCD and cancer.

Karlsson’s current projects include the Zoonomia Project, an international effort led by the Vertebrate Genomics group at the Broad to compare hundreds of different mammalian genomes and identify critically important segments of DNA.

Dr. Karlsson’s expanded bio
Follow Dr. Karlsson on Twitter

Dr. Lichtenfeld is a board-certified medical oncologist currently focused on health policy, COVID-19 response and impact on cancer care, and as an advisor/consultant to companies interested in better understanding cancer research, drug and technology development and patient access. He recently completed 19 years of service to the American Cancer Society including the roles of Deputy Chief Medical Officer and interim Chief Medical and Scientific Officer, co-leader for the Society’s nationwide response team for the corona virus pandemic and for 12 years managed the Society’s Cancer Control Science Department which was best known for the Society’s widely respected guidelines on the prevention and early detection of cancer.

Dr. Lichtenfeld has been widely quoted in the print and electronic media and is recognized for his expertise in medical policy and cancer care. He is well known for his blog which began in 2005 (www.cancer.org/drlen) and now continues at www.drlen.blog , focusing on various topics related to cancer research and treatment as well as COVID 19 and general medical care and policy.

Dr. Lichtenfeld’s expanded bio
Follow Dr. Lichtenfeld on Twitter

Christina Lopes is CEO and co-founder of The One Health Company, the leader in precision medicine for dogs with cancer. Christina has been recognized as Young Global Leader by the World Economic Forum at Davos for her pioneering efforts in both deal making and women’s health. Christina was managing director of Cerberus Capital, a $30 Billion-assets-under-management fund.

She was advisory board director for International Planned Parenthood (Western Hemisphere), which provides 30 million health services per year. Christina participated in The United Nations Commission for the Status of Women, and lectured at Columbia University. Christina was also honored a Rising Talent by the Women’s Forum in 2014.

She holds a B.A. from the University of Massachusetts, a Masters in International and Political Affairs from Columbia University, and Doctoral Coursework in Ethics at Princeton University. She loves dogs and bringing access to cutting edge healthcare. Christina lives in Palo Alto with her husband Ben and their two daughters.

Benjamin Lewis, Co-Founded One Health with Christina and is an animal health visionary, proud pet parent, and former Olympic athlete. Ben is committed to advancing cancer cures for dogs. Formerly, Ben was the co-founder and CEO of 4Vets, the largest B2B distributor of animal health products in Brazil.

Ben also represented the United States in the 2004 Olympics in Athens, Greece, where he served as captain of the K4. Ben studied bioengineering at Dartmouth College where he was inducted in the Dartmouth Hall of Fame (Wearer of the Green). In addition, Ben studied veterinary medicine at the University of Pennsylvania School of Veterinary Medicine, and has an MBA in Health Care Management at the Wharton School of Business.

Dr. Post is the Founder and Chief Medical Officer of The Veterinary Cancer Center, a specialized veterinary practice dedicated to the diagnosis and treatment of cancer in animals. He is one of only a few hundred board-certified veterinary oncologists in the United States and has more than 25 years of practice experience.

A New York native, Dr. Post earned a Bachelor of Science with distinction from Cornell University in 1983 and received his Doctor of Veterinary Medicine from the University of Minnesota in 1988. He completed a residency in Oncology at the Animal Medical Center – New York in 1991 and became a Diplomate of the American College of Veterinary Internal Medicine the following year.

He is the author or co-author of numerous articles, research papers, and book chapters in both oncology and hematology, including two seminal publications advancing treatment of both B-cell lymphoma and T-cell lymphoma in dogs.

Chase joined FidoCure as Chief Product Officer in 2022. He brings with him extensive experience in Genomics, Engineering, and Data Science. His passions are to bring together all the technical pieces of the puzzle to help move the world forward, helping animals and humans.

Prior to joining FidoCure, Chase spent over 5 years at Tempus Labs, joining as employee 90 and playing instrumental roles in Engineering, Data Science, Operations, and Science R&D while the company scaled to >2,000 employees. Chase’s role for the first 3 years was to scale the core business via both automation and launching new tests (moving from the first outsourced tissue panel to an in-house tissue test, along with the first liquid test). He moved on from there to launch Tempus’ algorithmic diagnostic business and led the launch of their HRD (Homologous Recombination Deficiency) and TO (Tumor of Unknown Origin) tests. For the last 1.5 years, Chase led the R&D Product and Strategy for the company. His main focus was leading strategic efforts in liquid biopsies and future assays.

Prior to Tempus, Chase filled a variety of roles for a FinTech startup, including being an Engineering lead and eventually leading their US Product team. Before that, he was a self-funded professional poker player throughout college, eventually moving into algorithmic trading and development at DRW.

Personally, Chase and his wife Cara moved to Boulder, Colorado last year, after 10 years in Chicago. They enjoy all the outdoor activities, and you’ll find them skiing, hiking, biking, running rock climbing, white water rafting, and all the other Colorado things. They have 2 dogs, 10 and 11 years old, and have been active in animal rights and animal rescue for quite some time.

Dr. Garrett Harvey is Manager of Veterinary Affairs and one of the staff veterinarians at the One Health Company. He initially joined FidoCure® as an intern and pursued a full-time role with the goal of developing professional relationships to align education and clinical genomic information to improve patient care. Dr. Harvey is passionate about helping dogs and their families unlock the potential of precision medicine and targeted therapies. He is also excited about elucidating the potential of translational oncology between canine and human patients.

Garrett is a Pennsylvania native, where he earned a Bachelor of Science with distinction at King’s College and completed his VMD (Veterinariae Medicinae Doctoris) at the University of Pennsylvania School of Veterinary Medicine. His desire to advance the integration and understanding of business management as it pertained to veterinary professionals and clinical practice also led him to complete multiple certificate courses through Harvard Business School. He remains active in a consultant role for a national nonprofit that provides business education for veterinary students and veterinarians.

As a lifelong learner, Dr. Harvey is interested in understanding the applications of “big data” in veterinary medicine. Garrett enjoys spending time with his fiancé, Meghan, and two terrific children. He is a sports enthusiast and proud pet parent to a marvelous German Shepherd named Rico who frequently participates in scent detection studies.

Lindsay joined the One Health Company in early 2017, with work experience in both clinical veterinary medicine as well as “Big Pharma” research. Her passion has always been animal welfare and was inspired by the idea of using comparative medicine to benefit both animals and people.

Prior to joining One Health, Lindsay spent more than a decade in the medical device industry at Ethicon, Inc, a Johnson & Johnson Company. She served in a number of capacities while at Ethicon, including Project Management, Regulatory/Compliance, as well as served as the Chair of their animal welfare committee and the project manager of the Johnson & Johnson Medical Device Global Animal Care & Use Council.

Prior to working at Ethicon, Lindsay spent several years working as a veterinary technician in private practice.

She holds a B.A. in Biology from Delaware Valley University and a Certificate in Clinical Research from Drexel University. She is also a Certified Professional IACUC Administrator (CPIA).

Dr. Michelle White joined FidoCure in 2022 as the Head of Science. She is particularly driven by excitement and urgency to use precision medicine to help dogs and humans. Ultimately, Dr. White is most passionate about treating each patient as an individual, using emerging technologies and insights to improve the lives of the animals and people we love.

During her freshman year at Harvard University, Michelle became enamored with genetics. She was fortunate to be accepted into the lab of Daniel Hartl PhD., where she focused on the interface between evolutionary biology and genomics. After graduating from Harvard, she spent several years as an internal consultant and retail analyst for retail companies in New York City. Michelle was later accepted to Cornell where she received first her DVM and later, a PhD in Translational Medicine working in the lab of Adam Boyko.

In 2020, Michelle joined Dr. Elinor Karlsson’s laboratory as a Senior Research Scientist at the University of Massachusetts Chan Medical School and the Broad Institute of MIT and Harvard. During her tenure there she collaborated with two FidoCure scientific advisory board members, Dr. Cheryl London and Dr. Corrie Painter.

Originally from Ohio, Michelle spent most of her adult life in both New York state (including NYC as well as Ithaca). Her husband Adam is a small animal surgery resident at the University of Wisconsin. They reside in Madison with their son, two cats (Sophie Von Cat and Squirrel) and a dog named Merlin. She loves home automation, fermenting foods, and speaks mainly in references from The Simpsons.

Dr. Lucas Rodrigues is a veterinarian at FidoCure® investigating the impact of DNA mutations on tumor behavior, evaluating treatment possibilities based on genomic profile, and performing scientific research for conferences and manuscript publications. He is an experienced investigator with deep knowledge in clinical oncology and molecular biology and 15 years of experience in comparative oncology.

Dr. Rodrigues received his Doctor of Veterinary Medicine from the University Paulista in São Paulo, Brazil. After that, he completed his Master and Ph.D. degree at the Universidade of São Paulo. He has significant experience in molecular biology, which was acquired during his 5 years of postdoctoral research at University of Wisconsin-Madison and Penn State University. He worked in several projects funded by The National Cancer Institute (NCI) and other agencies and has authored over 10 peer-reviewed journal papers and four book chapters.

During his postdoc work Dr. Rodrigues was the first to identify the expression of FZD-6 in osteosarcoma and suggest that the increased expression suppresses the Wnt/β-catenin signaling pathway, which in turn prevents the differentiation of cells and contributes to osteosarcoma tumor-initiating cells. While at Penn State University, he prepared the first study to report the critical role of IGF2BP1 in melanoma metastasis, in addition to being the first study to demonstrate the role of any RNA-binding protein in the extracellular vesicle-mediated promotion of metastasis.

Dr. Rodrigues is continuing his work in the field of cancer research developing personalized medicine for dogs with cancer through the use of cutting-edge technologies and taking the advantage of comparative oncology to also benefit human treatment against this devastating disease.

Aubrey joined the FidoCure®’s Clinical Operations team in 2019. She has always had a passion for medicine, specifically oncology, as she and her family run a non-profit organization giving back to families afflicted with cancer and other illnesses. As a dog lover herself, Aubrey was eager to join the mission of bringing personalized medicine to dogs.

Prior to joining FidoCure®, Aubrey worked in the fields of community health and clinical care. She also has experience in health program planning, implementation, and evaluation. She gained an interest in research having conducted several research projects during her undergraduate and graduate studies.

Aubrey holds a B.S. in Biology/Pre-Physician Assistant Studies and a Master of Public Health degree from East Stroudsburg University of Pennsylvania.

Jack joined the FidoCure® team as a consultant in 2019 to grow strategic partnerships in North America. He developed, expanded, and scaled the pet parent outreach program. After working as a consultant for 8 months, Jack was brought on as the director of growth, onboarding and managing a team of eager pet parent representatives.

Prior to joining FidoCure®, Jack spent more than 8 years working with tech startups, which included a TechStars alum and an acquisition by DropBox. His roles and responsibilities have ranged from the first salesperson hired, to running a team of 12. Previously his role as a sales strategy consultant involved acting as director of U.S. sales for several multinational companies and VC backed startups.

Abby joined the One Health Company in 2021 as a Clinical Operations Associate. She brings with her professional experience in veterinary oncological pharmaceutical development, veterinary emergency and critical care, feline-focused veterinary practice and clinical instruction of veterinary and veterinary technician students.

Abby became a certified Veterinary Technician in 2000, and in 2005, she attained certification as a Veterinary Technician Specialist in Emergency and Critical Care. She has a long history of both working for and volunteering in animal rescue and welfare. She is particularly fond of working with greyhounds, Spanish greyhounds, geriatric dogs and cats, hospice animals and cat Trap, Neuter, Release (TNR) programs.

Abby holds a B.A. in Technical Journalism from Colorado State University, and an A.A.S. in Veterinary Technology from Front Range Community College. She and her husband live on a large ranch in Northern Colorado, which they share with a rather large brood of dogs and cats.